Publications scientifiques

Depuis le 22/05/2026
  1. Reply to "A Comment about AI Methods that May Help Advance Pharmacovigilance".
    Khouri C, Hlavaty A, Fusaroli M, Joshi N, Salvo F, Bate A, Pariente A, Raschi E.
    Clin Pharmacol Ther. 2026
  2. Serious respiratory distress associated with bosentan administration in chronic thromboembolic pulmonary hypertension: A case report.
    Perino J, Bassan P, Salvo F, Miremont-Salamé G, Maurac A, Dournes G, Girodet PO.
    Therapie. 2026
  3. Comparison of the effect of donepezil and a combination of donepezil and mefloquine (THN201) on cognition during a scopolamine challenge in healthy participants.
    Dondaine T, Rein W, Micallef J, Cracowski JL, Girodet PO, Pickering G, Cracowski C, Thalamas C, Viardot G, L'Hostis P, Maurice D, Mouthon F, Charvériat M, Deplanque D, Bordet R.
    Exp Clin Psychopharmacol. 2026
  4. Face à la désinformation en santé, l’inaction n’est pas une option.
    Maisonneuve H, Costagliola D, Molimard M.
    Rev Prat. 2026
  5. [Assessing the risk-benefit balance of medicines: Some lessons from Covid-19]
    Cracowski JL, Molimard M, Richard V, Roustit M, Khouri C.
    Med Sci (Paris). 2026
  6. Sex Differences and Survival Among COPD Patients in France: The Palomb Cohort.
    Jestin-Guyon N, Ouaalaya EH, Bernady A, Berteaud E, Betancourt-Rial Z, Moinard J, Falque L, Le Guillou F, Molimard M, Nguyen L, Nocent C, Ozier A, Staali M, Raherison-Semjen C.
    Int J Chron Obstruct Pulmon Dis. 2026
  7. Drug prescription before and after dialysis initiation in older patients: a nationwide study.
    Faure L, Noize P, Couchoud C, Hucteau E, Berdougo J, Guerville F, Harambat J, Combe C, Levassort H, Moranne O, Hamroun A, Beuscart JB, Leffondré K, Prezelin-Reydit M; REIN registry.
    BMC Geriatr. 2026
  8. Addictive disorders and correlates in the context of chemsex practices: A French online survey.
    Pavirani L, Jakubiec L, Daveluy A, Cazanave C, Desnavailles P, Fatseas M.
    Addict Behav Rep. 2026
  9. PCSK9 inhibitors patterns of use in France from nationwide repeated cross-sectional and cohort studies.
    Singier A, Bénard-Laribière A, Jarne-Munoz A, Pariente A, Veyrac G, Bezin J.
    Sci Rep. 2026
  10. SGLT-2 Inhibitors Use in Hospitalized Patients in France: A Cross-Sectional Study.
    Demourgues M, Bezin J, Griffier R, Pariente A, Noize P, de Germay S.
    Fundam Clin Pharmacol. 2026
  11. Impact of secured prescription implementation on ambulatory pregabalin use in France: A regional assessment in the French Nouvelle-Aquitaine.
    Munech-Herran M, Moysan V, Lescarret B, Mathieu C, Pariente A, Rousselot N.
    Br J Clin Pharmacol. 2026
  12. Language models in pharmacovigilance: Applications, promises and limits.
    Salvo F, Crupi L, Cholle C.
    Therapie. 2026
  13. Coprescription of antipsychotics and benzodiazepines at hospital discharge.
    Demourgues M, Richaud A, Thiec J, Debruyne AL, Guillemin S, Tournier M, Salvo F, Queuille E.
    Encephale. 2026
  14. Drugs associated with generalized non-allergic pruritus: A World Health Organization pharmacovigilance database analysis.
    Kondor L, Cicala G, Salvo F, Clabecq C, Misery L, Brenaut E, Gourier G, Le Garrec R.
    J Am Acad Dermatol. 2026
  15. Hepatobiliary adverse drug reactions during treatment with olaparib: an analysis of data from the EudraVigilance reporting system.
    Velişcu EM, Cagnotta C, Sullo MG, Anatriello A, Salvo F, Scavone C.
    Front Drug Saf Regul. 2026
  16. How can the level of health product education (literacy) be raised among the general public?
    Locher C, Manaud N, Molimard M, Cassé-Perrot C, Cracowski JL, Di Palma C, Duchossoy L, Gatignol C, Goldgewicht A, Hertel O, Lacombe K, Lacroix C, Moreau-Chevrolet P, Quelet S, Rivière P, Lagouanelle MC, Micallef J.
    Therapie. 2026
  17. Standardizing and Comparing Management Recommendations for Potential Drug-Drug Interactions Across Different Interaction Checkers.
    Crupi L, Letinier L, Jouhet V, Cossin S, Pariente A, Mathieu C, Martin GL, Konschelle F, Rouanet J, Carollo M, Trifirò G, Esposito E, Salvo F.
    Drug Saf. 2026
  18. How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway?
    Body C, Chassagnol F, Berdaï D, Bergmann JF, Borget I, Doré C, Durr A, Falissard B, Hudry J, Kowalski B, Maugendre P, Schlumberger N, Wilmet É, Le Jeunne C.
    Therapie. 2026
  19. How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway?
    Body C, Chassagnol F, Berdaï D, Bergmann JF, Borget I, Doré C, Durr A, Falissard B, Hudry J, Kowalski B, Maugendre P, Schlumberger N, Wilmet E, Le Jeunne C.
    Therapie. 2025
  20. Impact of Regulatory Events on JAK Inhibitor Prescribing in Rheumatoid Arthritis: Insights from the French MAJIK Registry.
    Truchetet ME, Prati C, Thevenot P, Bologna C, Alegria GC, Daien CI, Cornec D, Dernis E, Fautrel B, Pariente A, Roux C, Salmon JH, Sellam J, Hucteau E, Bezin J, Avouac J.
    Joint Bone Spine. 2025